Table 1.
Demographic and clinical characteristics of the study population. Inflammatory bowel disease patients with neutralizing anti-drug antibodies and subtherapeutic trough levels are divided into patients receiving infliximab (left) and patients receiving adalimumab (right)
| Characteristics | IBD patients with pharmacokinetic LOR (n = 123) | |
|---|---|---|
| Infliximab (n = 87) | Adalimumab (n = 36) | |
| Demographics | ||
|
- Age, yrs (median [Q1, Q3]) - Females (n [%]) - BMI, kg/m2 (median [Q1, Q3]) |
45 (38, 54) 6 (46) 26 (23, 31) |
41 (32, 52) 20 (56) 29 (24, 33) |
| Smokers (n [%]) | 20 (23) | 9 (25) |
| Prior anti-TNF therapy (n [%]) | 32 (37) | 15 (42) |
| Prior immunomodulator therapy (n [%]) | 55 (63) | 27 (75) |
| Disease duration, yrs (median [Q1, Q3]) | 10 (6, 17) | 9 (5, 15) |
| Age at diagnosis, yrs (median [Q1, Q3]) | 30 (27, 33) | 31 (24, 40) |
| Disease type | ||
|
- Crohn’s disease - Ulcerative colitis |
61 (70) 26 (30) |
27 (75) 9 (25) |
| Crohn’s disease location (among respective patients) | ||
|
- Ileum isolated (n [%]) - Colon isolated (n [%]) - Ileocolic (n [%]) - Ileocolic + jejunum (n [%]) - Ileocolic + upper gastrointestinal tract (n [%]) |
3 (5) 14 (23) 30 (49) 4 (7) 10 (16) |
1 (4) 5 (19) 13 (48) 1 (4) 7 (26) |
| Extent of ulcerative colitis (among respective patients) | ||
|
- Proctitis (n [%]) - Left-sided colitis (n [%]) - Pancolitis (n [%]) |
4 (15) 9 (35) 13 (50) |
1 (11) 4 (44) 4 (44) |
| Complications | ||
|
- Fistula (n [%]) - Stenosis (n [%]) - Abscess (n [%]) - Extraintestinal manifestations (n [%]) - Perianal Crohn’s disease (n [%]) |
31 (36) 25 (29) 23 (26) 28 (32) 24 (28) |
16 (44) 15 (42) 10 (28) 17 (47) 11 (31) |
| Previous surgery (n [%]) | 44 (51) | 20 (56) |
ADA anti-drug antibodies, BMI body mass index, IBD inflammatory bowel disease, n number, Q1 lower (first) quartile, Q3 upper (third) quartile, yrs years